Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06420167 · ClinicalTrials.gov registry record · Phase 2
DapagliFLOzin in Renal AL Amyloidosis (FLORAL)
A Phase 2 study of Renal AL Amyloidosis, sponsored by Barbara Ann Karmanos Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06420167 is a Phase 2 study of Renal AL Amyloidosis that is actively recruiting participants, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06420167, a Phase 2 study of Renal AL Amyloidosis, is actively recruiting participants, sponsored by Barbara Ann Karmanos Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if an oral drug called dapagliflozin is safe and can reduce high protein levels in the urine of patients with renal amyloid light-chain (AL) amyloidosis using a decentralized study design. Participants will be: * screened for the trial via an online platform * contacted by study personal to obtain electronic consent * enrolled in the trial if eligible and consented * contacted by study personal for further instructions and directions * sent dapagliflozin oral medication (supplied by the site pharmacy) * followed up regularly with the study team via telemedicine or other online avenues * monitored using lab work, inquiries about side effects and assessment of protocol adherence at 1 month, 3 months and 6 months * continue treatment for 6 months
Conditions Studied
Interventions
- DRUG Dapagliflozin
Study Locations (1)
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-07-11 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06420167
The ClinicalTrials.gov registry entry for NCT06420167 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal AL Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which Dapagliflozin is the first listed.
NCT06420167 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT06420167 about?
NCT06420167 is a clinical study titled "DapagliFLOzin in Renal AL Amyloidosis (FLORAL)". The goal of this clinical trial is to learn if an oral drug called dapagliflozin is safe and can reduce high protein levels in the urine of patients with renal amyloid light-chain (AL) amyloidosis using a decentralized study design. Participants will be: * screened for the trial via an online plat...
What is the current status of trial NCT06420167?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-07-11. Estimated completion is 2027-04.
What conditions does trial NCT06420167 study?
This clinical trial studies the following conditions: Renal AL Amyloidosis.
What interventions are being tested in trial NCT06420167?
The interventions under investigation include: Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT06420167?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06420167 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.